(Q48302339)

10 February 2018

review article

1 reference

title

New developments in understanding the etiology of Parkinson's disease and in its treatment (English)

1 reference

10 February 2018

1 reference

2

1 reference

10 February 2018

Jonathan Dostrovsky

series ordinal

4

object named as

Dostrovsky JO

1 reference

10 February 2018

William Hutchison

series ordinal

3

object named as

Hutchison WD

1 reference

10 February 2018

Andres Lozano

series ordinal

1

object named as

Lozano AM

1 reference

10 February 2018

publication date

1 December 1998

1 reference

10 February 2018

Current Opinion in Neurobiology

published in

1 reference

10 February 2018

volume

8

1 reference

10 February 2018

issue

6

1 reference

10 February 2018

page(s)

783-790

1 reference

10 February 2018

Three-dimensional computer reconstruction of midbrain dopaminergic neuronal populations: from mouse to man

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

1 reference

7 January 2021

A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Alpha-synuclein in Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Models of basal ganglia function and pathophysiology of movement disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

The basal ganglia: focused selection and inhibition of competing motor programs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Neuronal circuitry and synaptic connectivity of the basal ganglia.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Effects of apomorphine on globus pallidus neurons in parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Levodopa: is toxicity a myth?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Motor complications of chronic levodopa therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Levodopa-induced dyskinesias are improved by fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Low-dose clozapine improves dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

The emerging role of clozapine in the treatment of movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Posteroventral medial pallidotomy in advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease. Six-month follow-up with additional 1-year observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Assessment of motor function after stereotactic pallidotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Neuronal xenotransplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Functional recovery in parkinsonian monkeys treated with GDNF

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-4388%2898%2980122-0

7 January 2021

10.1016/S0959-4388(98)80122-0

Identifiers

DOI

1 reference

10 February 2018

1 reference

10 February 2018